References
- Becker G, Blum HE. (2009). Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet 373:1198–206
- Chandrasekaran A, Tong Z, Li H, et al. (2010). Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans. Drug Metab Dispos 38:606–16
- European Medicines Agency. (2010). Relistor® (methylnaltrexone bromide solution) EU prescribing information [online]. Available from: URL:http://www.ema.europa.eu/humandocs/PDFs/EPAR/relistor/emea-combined-h870en.pdf [last accessed 13 Apr 2010]
- FDA/Center for Drug Evaluation and Research. (2008). Clinical Pharmacology and Biopharmaceutics Review(s) [Methyl-Naltrexone]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021964s000_ClinPharmR.pdf [last accessed 21 Oct 2010]
- Foss JF, O'connor MF, Yuan CS, et al. (1997). Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J Clin Pharmacol 37:25–30
- Goldberg LI, Merz H, Stockhaus K. (1978). Quaternary derivatives of noroxymorphone which relieve intestinal immobility. A61K 41/485 Edition. U.S. Patent 78-928821, 4176186
- Gough K, Hutchison M, Keene O, et al. (1995). Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J. 29:1039–48
- Jay T, Sloan K, Gail AC, et al. (2008). Methylnaltrexone for opioid induced constipation in advanced illness. N Engl J Med 358:2332–43
- Kotake AN, Kuwahara SK, Burton E, et al (1989). Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica 19:1247–54
- Peek R, Reddy KR. (2008). The food and drug administration approves methylnaltrexone bromide for opioid-induced constipation. Gastroenterology 135:6–7
- Prommer EE. (2015). Pharmacological management of cancer-related pain. Cancer Control 22:412
- Rauck RL. (2013). Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist methylnaltrexone. Drugs 73:1297–306
- Shimoyama N, Shimoyama M. (2013). Treatment of constipation in chronic pain patients. Masui 62:822–8
- Smith BP, Vandenhende FR, DeSante KA, et al. (2000). Confidence interval criteria for assessment of dose proportionality. Pharm Res 17:1278–83
- Turner AN, Maierhofer C, Funderburg NT, et al. (2016). High levels of self-reported prescription opioid use by HIV-positive individuals. AIDS Care 20: 1–7
- Yuan CS. (2007). Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 41:984–93
- Yuan CS, Wei G, Foss JF, et al. (2002). Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 300:118–23
- Yuan CS, Doshan H, Charney MR, et al. (2005). Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 45:538–46
- Webster LR. (2016). Chronic pain and the opioid conundrum. Anesthesiol Clin 34: 341–55
- Wyeth Pharmaceuticals Inc. (2010). Relistor® (methylnaltrexone bromide) subcutaneous injection: US prescribing information [online]. Available from: http://www.wyeth.com/content/showlabeling.asp?id=499 [lase accessed 13 Apr 2010]